Arguments to Support a Viral Origin of Oral Squamous Cell Carcinoma in Non-Smoker and Non-Drinker Patients.
EBV
HSV-2
herpesvirus
hit and run
non-smoker non-drinker
oral squamous cell carcinoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
07
2019
accepted:
28
04
2020
entrez:
13
6
2020
pubmed:
13
6
2020
medline:
13
6
2020
Statut:
epublish
Résumé
In some western countries, an increasing incidence of oral squamous cell carcinoma (OSCC) has been observed in non-smoker non-drinker patients (NSND), mostly in women with HPV-negative OSCC. In the context of the unknown etiology and mechanisms of tumorigenesis of OSCC in NSND, we discuss data supporting the hypothesis of a viral origin not related to HPV. OSCC from NSND are characterized by an antiviral DNA methylation and gene expression signature. Based on the similar increasing incidence of oral tongue SCC (OTSCC) and oropharyngeal SCC (OPSCC) in young women and men respectively, we hypothesize that changes in sexual behaviors may lead to an increasing incidence of herpesvirus in the oral cavity, especially HSV-2, similarly to what has already been described in HPV-positive OPSCC. Because viral genome integration has not been detected in OSCC from NSND, a "hit and run" viral mechanism involving epigenome deregulation could therefore play a key role at early steps of oral carcinogenesis in this population of patients. In conclusion, epidemiological, clinical and molecular data supports a "hit and run" viral origin of OSCC from NSND.
Identifiants
pubmed: 32528893
doi: 10.3389/fonc.2020.00822
pmc: PMC7253757
doi:
Types de publication
Journal Article
Langues
eng
Pagination
822Informations de copyright
Copyright © 2020 Foy, Bertolus, Boutolleau, Agut, Gessain, Herceg and Saintigny.
Références
Oral Oncol. 2017 Dec;75:178-179
pubmed: 29137848
Cancer Lett. 2011 Jun 28;305(2):200-17
pubmed: 20813452
Infect Agent Cancer. 2012 May 30;7(1):13
pubmed: 22647139
Int J Cancer. 2015 Jun 15;136(12):2752-60
pubmed: 25043222
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Ann Oncol. 2017 Aug 1;28(8):1934-1941
pubmed: 28460011
J Clin Oncol. 2011 Apr 10;29(11):1488-94
pubmed: 21383286
Sex Transm Infect. 2004 Aug;80(4):272-6
pubmed: 15295123
JAMA. 2014 Jan 8;311(2):183-92
pubmed: 24399557
Support Care Cancer. 2014 Jul;22(7):1773-9
pubmed: 24522744
Head Neck. 2015 Nov;37(11):1642-9
pubmed: 24954188
Oral Dis. 2012 Mar;18(2):178-83
pubmed: 22035108
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1829-34
pubmed: 17035389
Head Neck. 2008 Jan;30(1):75-84
pubmed: 17694557
Clin Cancer Res. 2013 Oct 1;19(19):5444-55
pubmed: 23894057
Oral Oncol. 2013 Jan;49(1):1-8
pubmed: 22841678
Head Neck Pathol. 2012 Jul;6 Suppl 1:S3-15
pubmed: 22782219
Int J Immunogenet. 2013 Aug;40(4):292-8
pubmed: 23442056
Cancer Res. 2009 Apr 1;69(7):2766-74
pubmed: 19339266
Head Neck. 2017 Feb;39(2):297-304
pubmed: 27696557
Biomed Pharmacother. 2016 Dec;84:552-558
pubmed: 27693964
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
PLoS One. 2017 Apr 20;12(4):e0176246
pubmed: 28426731
Cancer Lett. 2011 Jun 28;305(2):218-27
pubmed: 20971551
J Infect Dis. 2010 Sep 1;202(5):700-4
pubmed: 20653444
N Engl J Med. 2001 Apr 12;344(15):1125-31
pubmed: 11297703
Int J Cancer. 2019 Aug 1;145(3):775-784
pubmed: 30671943
J Virol. 2014 Oct;88(19):11442-58
pubmed: 25056883
J Virol. 2001 Apr;75(7):3089-94
pubmed: 11238835
Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2406-12
pubmed: 19745222
Nature. 2016 Jan 7;529(7584):43-7
pubmed: 26675728
Bioessays. 2012 Dec;34(12):1050-9
pubmed: 23012250
Am J Pathol. 2000 Jan;156(1):1-3
pubmed: 10623645
Cell Res. 2005 Apr;15(4):262-71
pubmed: 15857581
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
JAMA. 2001 Jun 27;285(24):3100-6
pubmed: 11427138
Oral Oncol. 2014 Jul;50(7):670-5
pubmed: 24735546
PLoS One. 2015 Nov 06;10(11):e0141695
pubmed: 26544609
Pharmacol Res. 2018 Jul;133:187-194
pubmed: 29753688
Oral Oncol. 2018 Nov;86:113-120
pubmed: 30409291
J Natl Cancer Inst. 2000 May 3;92(9):709-20
pubmed: 10793107
Cancer. 2005 May 1;103(9):1843-9
pubmed: 15772957
EBioMedicine. 2017 Mar;17:223-236
pubmed: 28314692
Nat Rev Genet. 2012 Jan 04;13(2):97-109
pubmed: 22215131
Oral Oncol. 2015 Mar;51(3):237-46
pubmed: 25560800
Oncotarget. 2016 Aug 9;7(32):51320-51334
pubmed: 27259999
J Virol. 2013 Aug;87(16):8916-26
pubmed: 23740984
Laryngoscope. 1999 Oct;109(10):1544-51
pubmed: 10522920
Oxid Med Cell Longev. 2016;2016:6021934
pubmed: 26977250
J Infect Dis. 2009 May 1;199(9):1263-9
pubmed: 19320589
Rev Med Virol. 2016 Sep;26(5):340-55
pubmed: 27273590
Clin Cancer Res. 2014 Jul 15;20(14):3842-8
pubmed: 24874835
Eur J Cancer. 2017 Sep;82:115-127
pubmed: 28654785
AIDS. 2010 May 15;24(8):1185-91
pubmed: 20299962
Mutat Res. 2011 May-Jun;727(3):55-61
pubmed: 21514401
Int J Environ Res Public Health. 2018 Dec 06;15(12):
pubmed: 30563223
Oral Oncol. 2014 May;50(5):387-403
pubmed: 24530208
Genes Dev. 2014 Dec 15;28(24):2679-92
pubmed: 25512556
Lancet. 2000 Sep 9;356(9233):871-2
pubmed: 11036888
Nature. 1983 Mar 3;302(5903):21-4
pubmed: 6298634
Br J Exp Pathol. 1976 Aug;57(4):361-76
pubmed: 183803
PLoS One. 2014 Jun 02;9(6):e98741
pubmed: 24887397